Drug intelligence / Profile preview

EMD 521873

Development stage: Phase 1
Lead developer: EMD Serono
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EMD 521873 (Selectikine) is a recombinant fusion protein immunocytokine that consists of a human antibody (NHS76) targeting necrotic DNA fused to a genetically modified human interleukin-2 (IL-2) moiety. The drug is designed to direct IL-2 activity specifically to tumor sites by binding exposed DNA in necrotic tumor regions. This targeted delivery aims to enhance anti-tumor immune responses while reducing systemic toxicity typically associated with IL-2 therapy. EMD 521873 was developed for the treatment of advanced solid tumors and hematological malignancies such as malignant melanoma and non-Hodgkin's lymphoma. Clinical studies demonstrated T-cell activation with limited NK cell activation and an improved safety profile compared to conventional IL-2 therapies[1][6][3].

Brand names: Selectikine
Other names: NHS-IL2NHS-IL-2NHS-IL 2SelectikineMSB0010445MSB-0010445MSB 0010445NHS-IL2-LTNHS-IL-2-LTNHS-IL 2-LT

Targets

ecDNA (Extracellular DNA in necrotic tumor tissue)IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on EMD 521873.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMD 521873.

Explore the full profile